EE41 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A Canada Public Payer Perspective
Abstract
Authors
J. Graham W. Kassouf D. Tomaras